286 related articles for article (PubMed ID: 16878345)
1. Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses.
Mandal R; Sawyer MB; Li XF
Rapid Commun Mass Spectrom; 2006; 20(17):2533-8. PubMed ID: 16878345
[TBL] [Abstract][Full Text] [Related]
2. Mass spectrometric studies of cisplatin-induced changes of hemoglobin.
Mandal R; Kalke R; Li XF
Rapid Commun Mass Spectrom; 2003; 17(24):2748-54. PubMed ID: 14673822
[TBL] [Abstract][Full Text] [Related]
3. Intact human holo-transferrin interaction with oxaliplatin.
Zhao YY; Mandal R; Li XF
Rapid Commun Mass Spectrom; 2005; 19(14):1956-62. PubMed ID: 15954173
[TBL] [Abstract][Full Text] [Related]
4. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
Mandal R; Kalke R; Li XF
Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
[TBL] [Abstract][Full Text] [Related]
5. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.
Allain P; Heudi O; Cailleux A; Le Bouil A; Larra F; Boisdron-Celle M; Gamelin E
Drug Metab Dispos; 2000 Nov; 28(11):1379-84. PubMed ID: 11038167
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
7. Characterization of intact hemoglobin and oxaliplatin interaction by nanoelectrospray ionization tandem mass spectrometry.
Peng J; Mandal R; Sawyer M; Li XF
Clin Chem; 2005 Dec; 51(12):2274-81. PubMed ID: 16195359
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
9. Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry.
Zhang W; Seymour L; Chen EX
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Dec; 876(2):277-82. PubMed ID: 19026601
[TBL] [Abstract][Full Text] [Related]
10. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
11. Short-term moderate exercise programs reduce oxidative DNA damage as determined by high-performance liquid chromatography-electrospray ionization-mass spectrometry in patients with colorectal carcinoma following primary treatment.
Allgayer H; Owen RW; Nair J; Spiegelhalder B; Streit J; Reichel C; Bartsch H
Scand J Gastroenterol; 2008 Aug; 43(8):971-8. PubMed ID: 18609189
[TBL] [Abstract][Full Text] [Related]
12. Analysis of urinary nucleosides as potential tumor markers in human colorectal cancer by high performance liquid chromatography/electrospray ionization tandem mass spectrometry.
Hsu WY; Chen WT; Lin WD; Tsai FJ; Tsai Y; Lin CT; Lo WY; Jeng LB; Lai CC
Clin Chim Acta; 2009 Apr; 402(1-2):31-7. PubMed ID: 19135043
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
14. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
15. Matrix-assisted laser desorption/ionization imaging mass spectrometry of oxaliplatin derivatives in heated intraoperative chemotherapy (HIPEC)-like treated rat kidney.
Bouslimani A; Bec N; Glueckmann M; Hirtz C; Larroque C
Rapid Commun Mass Spectrom; 2010 Feb; 24(4):415-21. PubMed ID: 20082287
[TBL] [Abstract][Full Text] [Related]
16. Studies of cisplatin and hemoglobin interactions using nanospray mass spectrometry and liquid chromatography with inductively-coupled plasma mass spectrometry.
Mandal R; Teixeira C; Li XF
Analyst; 2003 Jun; 128(6):629-34. PubMed ID: 12866879
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
[TBL] [Abstract][Full Text] [Related]
18. Rapid biotransformation of satraplatin by human red blood cells in vitro.
Carr JL; Tingle MD; McKeage MJ
Cancer Chemother Pharmacol; 2002 Jul; 50(1):9-15. PubMed ID: 12111106
[TBL] [Abstract][Full Text] [Related]
19. New techniques in the pharmacokinetic analysis of cancer drugs. II. The ultratrace determination of platinum in biological samples by inductively coupled plasma-mass spectrometry.
McKay K
Cancer Surv; 1993; 17():407-14. PubMed ID: 8137350
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
